Goldman Sachs’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $222K | Sell |
|
|||||
|
2025
Q1 | $851K | Buy |
|
|||||
|
2024
Q4 | $1.06M | Buy |
|
|||||
|
2024
Q3 | $347K | Sell |
|
|||||
|
2024
Q2 | $1.01M | Buy |
|
|||||
|
2024
Q1 | $181K | Sell |
|
|||||
|
2023
Q4 | $547K | Buy |
|
|||||
|
2023
Q3 | $1.87M | Sell |
|
|||||
|
2023
Q2 | $4.04M | Buy |
|
|||||
|
2023
Q1 | $2.4M | Sell |
|
|||||
|
2022
Q4 | $5.47M | Sell |
|
|||||
|
2022
Q3 | $6.65M | Buy |
|
|||||
|
2022
Q2 | $5.69M | Buy |
|
|||||
|
2022
Q1 | $4.46M | Buy |
|
|||||
|
2021
Q4 | $3.22M | Sell |
|
|||||
|
2021
Q3 | $7.94M | Buy |
|
|||||
|
2021
Q2 | $5.71M | Buy |
|
|||||
|
2021
Q1 | $3.04M | Buy |
|
|||||
|
2020
Q4 | $170K | Hold |
|
|||||
|
2020
Q3 | $68K | Sell |
|
|||||
|
2020
Q2 | $57K | Buy |
|
|||||
|
2020
Q1 | $25K | Sell |
|
|||||
|
2019
Q4 | $86K | Buy |
|
|||||
|
2019
Q3 | $46K | Sell |
|
|||||
|
2019
Q2 | $353K | Buy |
|
|||||
|
2019
Q1 | $580K | Sell |
|
|||||
|
2018
Q4 | $922K | Buy |
|
|||||
|
2018
Q3 | $1.39M | Buy |
|
|||||
|
2018
Q2 | $1.38M | Sell |
|
|||||
|
2018
Q1 | $1.74M | Buy |
|
|||||
|
2017
Q4 | $1.77M | Sell |
|
|||||
|
2017
Q3 | $2.39M | Buy |
|
|||||
|
2017
Q2 | $2.17M | Buy |
|
|||||
|
2017
Q1 | $1.03M | Buy |
|